IMS Health
The viability of a research program can hinge upon a drug sponsor's success in negotiating a fair market price-including overhead rates-with investigators. Ultimately, when these contract costs don't align with the trial budget, sponsors end up squandering valuable resources.
Understanding site overhead expenses—those not directly related to conducting clinical studies—is a critical component of setting a fair market price for grants. Indeed, the overhead rate can be the single largest line item in a sponsor's study budget.
Yet, site overhead rates are commonly misunderstood, especially as they vary greatly by institution; they can range anywhere from 25% to 40% of the site's overall budget. Knowing where site overhead expenses fall within that range can be the key difference between developing a realistic budget for grants that sites will accept and developing a study budget that is grossly over or under funded.
Key overhead expenses include business development, insurance, information technology, supplies, and human resources. Also included are depreciation, profit (generally calculated at 8%), costs to attend industry conferences, occupancy (rent, power, and security), legal and accounting services, laundry and waste disposal, internal accounting, and interest expenses. Alternately, overhead can be considered an opportunity cost by representing the return on assets used to conduct the study (cash, property, furniture, equipment, supplies, etc.) that could otherwise be directed toward other profitable activities.
IMS Health has analyzed overhead rates by region, incorporating data from over 60 countries, 16 therapeutic areas, and more than 150,000 grants. Figure 1 shows the increase in overhead rates by region over the past three years. While the United States has generally had the highest overhead costs (24.9%) for all study phases, costs are rising most rapidly in emerging economies. As has been the case in other regions, we can expect these increases to level off once sites in these areas are more stable.
Overhead costs should be considered when selecting the best countries and sites for trials.
Overhead costs are significant enough that they should be one of many factors considered when selecting the best countries and sites for trials. Properly planning for sites' overhead costs requires an understanding of how expenses vary by geographic area and how those costs change over time. Budgets should be based on the most current information, given how rapidly things change in some regions.
—IMS Health (for more information contact clinicaltrials@us.imshealth.com)
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.